Related Experiment Video

Updated: Jul 6, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

Francis Y F Lee1, Richard Smykla, Kathy Johnston

  • 1Oncology Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, K22-03, Princeton, NJ 08540, USA. francis.lee@bms.com

Cancer Chemotherapy and Pharmacology
|March 20, 2008
PubMed
Abstract

Insights

Ixabepilone shows potent anticancer activity across various tumor types, overcoming common drug resistance mechanisms. Its favorable pharmacokinetics support its role as a novel antineoplastic agent.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Ixabepilone is a semisynthetic analog of epothilone B, developed for cancer treatment.
  • Previous research indicated ixabepilone's efficacy and low susceptibility to tumor resistance mechanisms.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetics of ixabepilone as an antineoplastic agent.
  • To investigate ixabepilone's activity against multidrug-resistant cancer models.

Main Methods:

  • In vitro cytotoxicity assays in breast, lung, and colon tumor cell lines.
  • In vivo studies using human xenografts and multidrug-resistant models.
  • Assessment of drug uptake in P-glycoprotein (P-gp)-resistant models and pharmacokinetic profiling in mice and humans.

Main Results:

  • Ixabepilone demonstrated potent cytotoxicity in vitro and in vivo across a broad spectrum of human cancers.
  • It was significantly more potent than docetaxel in a paclitaxel-resistant xenograft model.
  • Ixabepilone showed activity against P-gp-overexpressing cancers and was taken up by P-gp-overexpressing cells, unlike paclitaxel.

Conclusions:

  • Ixabepilone exhibits potent, broad-spectrum antineoplastic activity with favorable pharmacokinetics.
  • It effectively overcomes resistance mechanisms including P-gp overexpression and tubulin alterations.
  • Ixabepilone represents a promising agent for cancer treatment, particularly in resistant cases.

More Related Videos

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...